<?xml version="1.0" encoding="UTF-8"?>
<p>There are a few experimental and computational approaches examining the possibility of usage of known antiviral drugs, including those employed for the treatment of viral hepatitis C and antiretroviral drugs, to treat SARS-CoV-2 [
 <xref rid="B7-molecules-25-02944" ref-type="bibr">7</xref>,
 <xref rid="B8-molecules-25-02944" ref-type="bibr">8</xref>,
 <xref rid="B9-molecules-25-02944" ref-type="bibr">9</xref>]. There are several studies describing the treatment of SARS-CoV-2 using antiretroviral drugs, such as remdesivir [
 <xref rid="B10-molecules-25-02944" ref-type="bibr">10</xref>], lopinavir/ritonavir, and darunavir [
 <xref rid="B9-molecules-25-02944" ref-type="bibr">9</xref>,
 <xref rid="B11-molecules-25-02944" ref-type="bibr">11</xref>]. The molecular mechanism of action of lopinavir/ritonavir has been discussed [
 <xref rid="B12-molecules-25-02944" ref-type="bibr">12</xref>,
 <xref rid="B13-molecules-25-02944" ref-type="bibr">13</xref>,
 <xref rid="B14-molecules-25-02944" ref-type="bibr">14</xref>]. Their application for the treatment of COVID-19 as monotherapies [
 <xref rid="B12-molecules-25-02944" ref-type="bibr">12</xref>] or in combination with other drugs [
 <xref rid="B13-molecules-25-02944" ref-type="bibr">13</xref>] has been shown.
</p>
